Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 9,659,086 shares, a growth of 46.4% from the October 15th total of 6,598,711 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 7,815,853 shares, the days-to-cover ratio is presently 1.2 days.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. New Street Research set a $43.00 price target on shares of Genmab A/S in a report on Wednesday, July 22nd. Morgan Stanley cut their price objective on shares of Genmab A/S from $57.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday. JPMorgan Chase & Co. raised shares of Genmab A/S from a "neutral" rating to an "overweight" rating in a research note on Monday, October 26th. Guggenheim upped their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Genmab A/S from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $53.50.
View Our Latest Analysis on Genmab A/S
Institutional Investors Weigh In On Genmab A/S
A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. First Trust Advisors LP boosted its position in Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock valued at $66,038,000 after buying an additional 1,126,069 shares during the period. Renaissance Technologies LLC grew its holdings in Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock worth $118,442,000 after acquiring an additional 921,700 shares during the last quarter. Great Point Partners LLC bought a new stake in Genmab A/S in the 3rd quarter worth $18,729,000. Marshall Wace LLP increased its position in shares of Genmab A/S by 47.0% in the third quarter. Marshall Wace LLP now owns 1,219,998 shares of the company's stock valued at $43,517,000 after acquiring an additional 390,339 shares during the period. Finally, HighVista Strategies LLC purchased a new position in shares of Genmab A/S in the third quarter valued at about $8,066,000. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Price Performance
NASDAQ:GMAB traded up $0.39 during trading hours on Tuesday, hitting $51.96. 3,322,111 shares of the company's stock traded hands, compared to its average volume of 2,577,254. The firm has a market cap of $32.43 billion, a P/E ratio of 44.41, a P/E/G ratio of 2.08 and a beta of 0.73. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $59.97. The business's fifty day simple moving average is $41.51 and its two-hundred day simple moving average is $31.70. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.36 by $0.20. The business had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. On average, research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current fiscal year.
About Genmab A/S
(
Get Free Report)
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.